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To date, human studies in a dialysis population have conﬁrmed
the pharmacokinetic differences in half life and clearance between
NESP and r-HuEPO (Macdougall, 1999). However, studies in
humans using NESP have shown an efﬁcacy proﬁle that is compar-
able to r-HuEPO (Coyne et al, 2000; Nissenson et al, 2000;
Locatelli et al, 2001). These studies reinforce the fact that results
garnered from animal models are not necessarily indicative of what
is to be ascertained in humans.
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Sir
The development of darbepoetin alfa (NESP, ARANESP
TM) was an
outgrowth of basic research directed towards elucidating those
structural features that control the in vivo biological activity of
erythropoietin (EPO). As described in our study, this research
demonstrated that serum clearance is the primary determinant of
EPO in vivo biological activity, and that serum clearance can be
manipulated by changing the proportion of sialic acid-containing
carbohydrate. Molecules having a higher proportion of sialic
acid-containing carbohydrate have a longer serum half-life and
thereby a higher in vivo biological activity. These principles,
gleaned from natural sequence EPO, were applied and extended
to speciﬁcally engineer a new molecule, NESP. Our review article
(Egrie and Browne, 2001) summarized the basic research leading
to the design of NESP and summarized the results of comparative
pharmacodynamic studies of NESP and rHuEPO.
As we stated in our article, the relative potency of NESP and
rHuEPO were determined in a normal mouse animal model in
which both molecules produced dose-dependent increases in
hematocrit. These studies were performed using three different
routes of administration and three different dosing frequencies.
For each route, frequency, and test article, multiple doses were
tested which covered the entire dose response range. The results
of these experiments were used to construct relative potency
plots (log dose response curves). The relative potency was then
determined as the ratio of equieffective doses of each from their
respective graded dose–response relations (Tallarida and Murray,
1987). When data from all studies were combined (nine experi-
ments using 1185 animals), NESP was determined to be 3.6-fold
more potent than rHuEPO for each route of administration
when given three times per week. That is, it takes 3.6-fold more
rHuEPO to obtain the same biological response as NESP. As a
corollary, when equimolar doses of NESP and rHuEPO are
compared, rHuEPO produces a lower biological response, as is
illustrated in our Figure 5 and noted in paragraph 3 of Dr *Correspondence: J Egrie; E-mail: joanne@amgen.com
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administered once weekly, NESP was determined to be 13-fold
more potent than rHuEPO. Relative potency plots were also used
to compare once weekly with thrice weekly administration for
each molecule. When rHuEPO was administered once weekly,
an *15-fold higher total weekly dose was required to achieve
the same biological response as when rHuEPO was administered
thrice weekly. In contrast, for NESP only a 4-fold dose increase
was required for once versus thrice weekly administration. As we
stated in our article, due to the pharmacokinetic differences
between NESP and rHuEPO (NESP has a 3-fold longer serum
half-life than rHuEPO in animals and man) no one number
can be used to express the relative potency difference between
the two molecules. The relative potency of NESP and rHuEPO
will necessarily change as a function of the dosing interval. Long-
er dosing intervals will lead to greater observed potency
advantages for NESP.
As we cautioned in our review, one should be careful not to
extrapolate the ﬁndings from an animal model to a human clinical
setting. We cited the ﬁndings (Macdougall, 1998) from the ﬁrst
study of NESP in naı ¨ve dialysis patients, which did not show a
difference in the NESP dose required once versus thrice weekly,
and we suggested that the differences in erythrokinetics and red cell
lifespan between the two species could account for this difference.
Results from phase III clinical studies in chronic renal failure
patients, however, conﬁrm that the signiﬁcantly longer serum
half-life of NESP confers the clinical advantage of less frequent
dosing compared with rHuEPO. In a crossover clinical study in
dialysis patients, 97% of patients whose baseline rHuEPO dose
frequency was two or three times per week, were successfully main-
tained on the same total weekly dose of NESP given once weekly or
less frequently. In addition, in this study 95% of patients whose
baseline rHuEPO therapy was once weekly were successfully main-
tained on NESP given once every other week (Vanrenterghem et al,
1999). Maintenance of Hgb level, weekly dose requirement and the
frequency of dose changes in the NESP and rHuEPO groups were
similar regardless of route of administration, even among NESP
patients dosed once every other week. In the oncology setting,
rHuEPO can be administered as infrequently as once a week
(Gabrilove et al, 2001). In contrast, for NESP in the oncology
setting, studies have clearly demonstrated that Hgb levels could
be maintained when NESP was administered as infrequently as
once every three or four weeks (Kotasek et al, 2000, 2002; Smith
et al, 2002). In total, these studies indicate that NESP provides
the clinical beneﬁt of less frequent dosing.
As Dr Malonne noted, the ﬁve amino acid changes made to
design NESP could have consequences on the structure of the
molecule. Although biophysical characterisation of NESP was not
the subject of our review, we report here that the tertiary structures
of the NESP and rHuEPO polypeptides are virtually indistinguish-
able by a variety of different tests. However, as stated in our article,
since any change in the primary, secondary or tertiary structure of
a protein may be recognised by the immune system of treated
patients, all patients in clinical studies have been carefully moni-
tored for the development of an immune response. Signiﬁcantly,
in all clinical trials, involving over 10000 patients, there has been
no evidence of antibody formation.
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